NCT06391827View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and PK of DA-7503 in Healthy Adult and Elderly Participants

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 7, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions
Healthy
Interventions
DRUG

DA-7503 Single dose

Oral administration for once; Dose strength is different for each cohort(Cohort 1, 2, 3, 4 and 5).

DRUG

DA-7503 Multiple dose

Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)

DRUG

Placebo Single dose

Oral administraion for once.

DRUG

Placebo Multiple dose

Oral administration once daily for 7 days

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY